ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

317
Analysis
Health Care • China
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
bearish•WH Group
•07 Jan 2025 13:21

WH Group (288 HK): Smithfield's IPO Doc Now Out

WHG could surprise the market with a higher than expected IPO price. I doubt it. Even applying a high-end value for Smithfield of ~US$10bn, a ~38%...

Logo
588 Views
Share
•06 Jan 2025 11:38

Boqi Env (2377 HK): Takeaways From The Partial Offer

~45% of the public shareholders tendering has been a useful benchmark in past Hong Kong Partial Offers, and so it was again for Boqi.

Logo
415 Views
Share
bullish•Insignia Financial
•06 Jan 2025 09:04

Insignia Financial (IFL AU): CC Capital Wades In With A $4.30/Share NBIO

Terms are non-binding. I think IFL should engage here. However, I'm not confident Tanarra is willing to kick out at a 7.5% premium to Bain's terms.

Logo
445 Views
Share
bullish•Vesync
•06 Jan 2025 02:14

Merger Arb Mondays (06 Jan) - Vesync, Canvest, Get Nice, Fosun Tourism, GAPack, HKBN, Seven & I

This week, the highest gross spreads are Seven & I (15.0%), Get Nice Financial (11.6%),  Arcadium Lithium (11.0%), ESR (8.9%), Goldlion (7.3%),...

Logo
726 Views
Share
bullish•Viva Goods
•03 Jan 2025 12:21

Bossini (592 HK): 10th Feb Scheme Vote

The spread is there and Viva is shortable.  Not sure if you can take down borrow cheaply. Otherwise, this is an avoid. Viva is trading rich. It may...

Logo
668 Views
Share
x